The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy

• Main Authors: Angioletta Lasagna (Author), Dalila Mele (Author), Federica Bergami (Author), Domiziana Alaimo (Author), Chiara Dauccia (Author), Nicolò Alessio (Author), Giuditta Comolli (Author), Francesca Pasi (Author), Alba Muzzi (Author), Viola Novelli (Author), Fausto Baldanti (Author), Paolo Pedrazzoli (Author), Irene Cassaniti (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTHerpes zoster (HZ) is caused by the reactivation of latent varicella zoster virus (VZV). Severe immunocompromising conditions, such as solid tumors, have been largely associated with an increased risk for HZ due to waning VZV-specific cellular immunity. With the approval of the adjuvanted gl...